Baseline Metabolic Tumour Volume is an Independent Prognostic Factor in Hodgkin Lymphoma

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2014 May 10

PMID 24811577

Citations 66

Authors

Salim Kanoun

Cedric Rossi

Alina Berriolo-Riedinger

Inna Dygai-Cochet

Alexandre Cochet

Olivier Humbert

Michel Toubeau

Emmanuelle Ferrant

Francois Brunotte

Rene-Olivier Casasnovas

Affiliations

Soon will be listed here.

Abstract

Purpose: The presence of a bulky tumour at staging in Hodgkin lymphoma (HL) is a predictor of a poor outcome. The total metabolic tumour volume at baseline (TMTV0) computed on PET may improve the evaluation of tumour burden. To explore the clinical usefulness of TMTV0, we compared the prognostic value of TMTV0, tumour bulk and interim PET response in a retrospective single-centre study.

Methods: From 2007 to 2010, 59 consecutive patients with a first diagnosis of HL were treated in our institution. PET was done at baseline (PET0) and after two cycles of chemotherapy (PET2), and treatment was not modified according to the PET2 result. TMTV0 was measured with a semiautomatic method using a 41 % SUVmax threshold. SUVmax reduction between PET0 and PET2 (ΔSUVmaxPET0-2) was also computed. Based on ROC analysis, patients with a ΔSUVmaxPET0-2 >71 % were considered good responders and a TMTV0 >225 ml was considered to represent hypermetabolic bulky disease.

Results: Median TMTV0 was 117 ml and 17 patients (29 %) had a TMTV0 >225 ml. TMTV0 (>225 ml vs. ≤225 ml) and tumour bulk (<10 cm vs. ≥10 cm) were predictive of 4-year PFS: 42 % vs. 85 % (p = 0.001) and 44 % vs. 79 % (p < 0.03), respectively. In multivariate analysis, using ΔSUVmaxPET0-2, TMTV0 and bulky tumour as covariates, only ΔSUVmaxPET0-2 (p = 0.0005, RR 6.3) and TMTV0 (p < 0.006, RR 4.4) remained independent predictors of PFS. Three prognosis groups were thus identified: ΔSUVmaxPET0-2 >71 % and TMTV0 ≤225 ml (n = 37, 63 %), ΔSUVmaxPET0-2 = <71 % or TMTV0 >225 ml (n = 17, 29 %), and ΔSUVmaxPET0-2 = <71 % and TMTV0 >225 ml (n = 5, 8 %). In these three groups the 4-year PFS rates were 92 %, 49 %, and 20 % (p < 0.0001), respectively.

Conclusion: TMTV0 is more relevant than tumour bulk for predicting the outcome in patients with HL, and adds a significant prognostic insight to interim PET response assessment. The combination of TMTV0 and ΔSUVmaxPET0-2 made it possible to identify three subsets of HL patients with different outcomes. This may guide clinicians in their choice of therapeutic strategy.

Citing Articles

Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study.

Malmon S, Casasnovas O, Fournier M, Cartron G, Kanoun S, Cottereau A Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39984744 DOI: 10.1007/s00259-025-07154-w.

Postoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?.

Couturier A, Judet A, Touati M, Nivet T, Daufresne P, Claves F Hemasphere. 2025; 9(1):e70076.

PMID: 39816530 PMC: 11733436. DOI: 10.1002/hem3.70076.

Semiquantitative 2-[F]FDG PET/CT-based parameters role in lymphoma.

Albano D, Ravanelli M, Durmo R, Versari A, Filice A, Rizzo A Front Med (Lausanne). 2025; 11:1515040.

PMID: 39744526 PMC: 11688351. DOI: 10.3389/fmed.2024.1515040.

Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.

Draye-Carbonnier S, Camus V, Becker S, Tonnelet D, Leveque E, Zduniak A Sci Rep. 2024; 14(1):8033.

PMID: 38580734 PMC: 10997640. DOI: 10.1038/s41598-024-58412-0.

A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters.

Aksu A, Kucuker K, Solmaz S, Turgut B Ann Hematol. 2023; 103(3):813-822.

PMID: 37964021 DOI: 10.1007/s00277-023-05547-1.

References

Tseng D, Rachakonda L, Su Z, Advani R, Horning S, Hoppe R . Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol. 2012; 7:5. PMC: 3398283. DOI: 10.1186/1748-717X-7-5. View

Gobbi P, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E . Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012; 30(4):194-9. DOI: 10.1002/hon.1024. View

Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J . Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48(10):1626-32. DOI: 10.2967/jnumed.107.042093. View

Connors J . Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011:317-22. DOI: 10.1182/asheducation-2011.1.317. View

Hasenclever D, Diehl V . A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998; 339(21):1506-14. DOI: 10.1056/NEJM199811193392104. View

Moog F, Bangerter M, Diederichs C, Guhlmann A, Merkle E, Frickhofen N . Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998; 206(2):475-81. DOI: 10.1148/radiology.206.2.9457202. View

Shreve P, Anzai Y, Wahl R . Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999; 19(1):61-77; quiz 150-1. DOI: 10.1148/radiographics.19.1.g99ja0761. View

Gobbi P, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V . Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2011; 11(5):396-402. DOI: 10.1016/j.clml.2011.04.008. View

Hatt M, Boussion N, Cheze-Le Rest C, Visvikis D, Pradier O . [Metabolically active volumes automatic delineation methodologies in PET imaging: review and perspectives]. Cancer Radiother. 2011; 16(1):70-81. DOI: 10.1016/j.canrad.2011.07.243. View

10.

Eichenauer D, Engert A, Dreyling M . Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:vi55-8. DOI: 10.1093/annonc/mdr378. View

11.

El-Galaly T, DAmore F, Mylam K, de Nully Brown P, Bogsted M, Bukh A . Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012; 30(36):4508-14. DOI: 10.1200/JCO.2012.42.4036. View

12.

Song M, Chung J, Shin H, Lee S, Lee S, Lee H . Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2011; 91(5):697-703. PMC: 3319905. DOI: 10.1007/s00277-011-1357-2. View

13.

Zinzani P, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E . Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006; 17(8):1296-300. DOI: 10.1093/annonc/mdl122. View

14.

Cheson B . Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011; 29(14):1844-54. DOI: 10.1200/JCO.2010.32.5225. View

15.

Hyun S, Choi J, Kim K, Kim J, Shim Y, Um S . Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2012; 257(2):364-70. DOI: 10.1097/SLA.0b013e318262a6ec. View

16.

Zhang H, Wroblewski K, Liao S, Kampalath R, Penney B, Zhang Y . Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol. 2012; 20(1):32-40. DOI: 10.1016/j.acra.2012.07.002. View

17.

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

18.

Park G, Kim J, Roh J, Choi S, Nam S, Kim S . Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2012; 24(1):208-14. DOI: 10.1093/annonc/mds247. View

19.

Shum W, Ding H, Liang J, Yen K, Chen S, Kao C . Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of esophagus treated by curative surgery. Anticancer Res. 2012; 32(9):4163-8. View

20.

Specht L, NORDENTOFT A, Cold S, Clausen N, Nissen N . Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988; 61(8):1719-27. DOI: 10.1002/1097-0142(19880415)61:8<1719::aid-cncr2820610834>3.0.co;2-a. View